These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36018230)

  • 1. Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE.
    Mysler E; Tanaka Y; Kavanaugh A; Aletaha D; Taylor PC; Song IH; Shaw T; Song Y; DeMasi R; Ali M; Fleischmann R
    Rheumatology (Oxford); 2023 May; 62(5):1804-1813. PubMed ID: 36018230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
    Fleischmann R; Pangan AL; Song IH; Mysler E; Bessette L; Peterfy C; Durez P; Ostor AJ; Li Y; Zhou Y; Othman AA; Genovese MC
    Arthritis Rheumatol; 2019 Nov; 71(11):1788-1800. PubMed ID: 31287230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.
    Fleischmann RM; Genovese MC; Enejosa JV; Mysler E; Bessette L; Peterfy C; Durez P; Ostor A; Li Y; Song IH
    Ann Rheum Dis; 2019 Nov; 78(11):1454-1462. PubMed ID: 31362993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis.
    Fleischmann RM; Blanco R; Hall S; Thomson GTD; Van den Bosch FE; Zerbini C; Bessette L; Enejosa J; Li Y; Song Y; DeMasi R; Song IH
    Ann Rheum Dis; 2021 Apr; 80(4):432-439. PubMed ID: 33148701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program.
    Peterfy CG; Strand V; Friedman A; Hall S; Mysler E; Durez P; Baraliakos X; Enejosa JV; Shaw T; Li Y; Chen S; Song IH
    Rheumatology (Oxford); 2022 Aug; 61(8):3246-3256. PubMed ID: 34897366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study.
    Fleischmann R; Swierkot J; Penn SK; Durez P; Bessette L; Bu X; Khan N; Li Y; Peterfy CG; Tanaka Y; Mysler E
    RMD Open; 2024 May; 10(2):. PubMed ID: 38806190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE.
    Fleischmann R; Blanco R; Van den Bosch F; Bessette L; Song Y; Penn SK; McDearmon-Blondell E; Khan N; Chan K; Mysler E
    Rheumatol Ther; 2024 Jun; 11(3):599-615. PubMed ID: 38498140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative remission rates of Janus kinase inhibitors in comparison with adalimumab in patients with active rheumatoid arthritis: a network meta-analysis.
    Lee YH; Song GG
    Z Rheumatol; 2024 Feb; 83(Suppl 1):88-96. PubMed ID: 35142908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE.
    Strand V; Tundia N; Bergman M; Ostor A; Durez P; Song IH; Enejosa J; Schlacher C; Song Y; Fleischmann R
    Rheumatology (Oxford); 2021 Dec; 60(12):5583-5594. PubMed ID: 33590829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial.
    van Vollenhoven R; Strand V; Takeuchi T; Chávez N; Walter PM; Singhal A; Swierkot J; Khan N; Bu X; Li Y; Penn SK; Camp HS; Aelion J
    Arthritis Res Ther; 2024 Jul; 26(1):143. PubMed ID: 39075620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND.
    van Vollenhoven RF; Hall S; Wells AF; Meerwein S; Song Y; Tanjinatus O; Fleischmann R
    RMD Open; 2024 Jul; 10(3):. PubMed ID: 39053948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme.
    Cohen SB; van Vollenhoven RF; Winthrop KL; Zerbini CAF; Tanaka Y; Bessette L; Zhang Y; Khan N; Hendrickson B; Enejosa JV; Burmester GR
    Ann Rheum Dis; 2021 Mar; 80(3):304-311. PubMed ID: 33115760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
    Smolen JS; Pangan AL; Emery P; Rigby W; Tanaka Y; Vargas JI; Zhang Y; Damjanov N; Friedman A; Othman AA; Camp HS; Cohen S
    Lancet; 2019 Jun; 393(10188):2303-2311. PubMed ID: 31130260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in Ultrasonographic Vascularity Upon Initiation of Adalimumab Combination Therapy in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate.
    Kaeley GS; Nishio MJ; Goyal JR; MacCarter DK; Wells AF; Chen S; Kupper H; Kalabic J
    Arthritis Rheumatol; 2016 Nov; 68(11):2584-2592. PubMed ID: 27214046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials.
    Bergman M; Buch MH; Tanaka Y; Citera G; Bahlas S; Wong E; Song Y; Zueger P; Ali M; Strand V
    Rheumatol Ther; 2022 Dec; 9(6):1517-1529. PubMed ID: 36125701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Responses and Synovial Vascularity in Obese Rheumatoid Arthritis Patients Treated with Adalimumab and Methotrexate.
    Kaeley GS; MacCarter DK; Pangan AL; Wang X; Kalabic J; Ranganath VK
    J Rheumatol; 2018 Dec; 45(12):1628-1635. PubMed ID: 30173153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study.
    Rubbert-Roth A; Kato K; Haraoui B; Rischmueller M; Liu Y; Khan N; Camp HS; Xavier RM
    Rheumatol Ther; 2024 Oct; 11(5):1197-1215. PubMed ID: 39031276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
    Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
    Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upadacitinib
    Pavelka K; Szekanecz Z; Damjanov N; Anić B; Tomšič M; Mazurov V; Maksimovic M; Nagy O; Świerkot J; Petranova T; Veldi T; Baranauskaitė A; Codreanu C; Andersone D; Fleischmann R
    Drugs Context; 2020; 9():. PubMed ID: 33123205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme.
    Fleischmann R; Curtis JR; Charles-Schoeman C; Mysler E; Yamaoka K; Richez C; Palac H; Dilley D; Liu J; Strengholt S; Burmester G
    Ann Rheum Dis; 2023 Sep; 82(9):1130-1141. PubMed ID: 37308218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.